Mouse thymus single-cell suspension (about 90% CD4⁺CD8⁺ double-positive) depleted with anti-mouse CD8 Nanobeads: residual CD8⁺ in the flow-through was 13.92% versus 67.50% for the competitor, and the target CD4⁺CD8⁸ population rose from 30.8% to 80.4%. Both products used the same bead volume, 90 μL per sample.
Mouse thymus single-cell suspension (about 90% CD4⁺CD8⁺ double-positive) depleted with anti-mouse CD8 Nanobeads: residual CD8⁺ in the flow-through was 13.92% versus 67.50% for the competitor, and the target CD4⁺CD8⁸ population rose from 30.8% to 80.4%. Both products used the same bead volume, 90 μL per sample.
The experiment was designed and run by the customer. Both products were used on the same kind of mouse thymus preparation with the same bead volume, so the difference does not come from bead dosing. The two readings answer different questions: positive-selection purity asks “how clean is what was captured”, while flow-through residual asks “how much of the target was actually removed”. Here the first was comparable and the second was not.
| Quadrant | Population | Binding: competitor | Binding: PM008 | Flow-through: competitor | Flow-through: PM008 |
|---|---|---|---|---|---|
| Upper right | CD4⁺CD8⁺ (DP) | 99.0% | 98.1% | 66.0% | 13.7% |
| Lower right | CD4⁸CD8⁺ (SP8) | 0.53% | 0.85% | 1.50% | 0.22% |
| Upper left | CD4⁺CD8⁸ (SP4, target) | 0.16% | 0.0322% | 30.8% | 80.4% |
| Lower left | Double negative | 0.28% | 0.98% | 1.71% | 5.73% |
| Total CD8⁺ (DP + SP8) | 99.53% | 98.95% | 67.50% | 13.92% | |
Tell us your sample type (whole blood or PBMC), the volume you start from and the downstream assay — we will suggest a separation route, a column and the matching catalogue numbers.